Key facts
- Cynaptec Pharmaceuticals’s last known valuation is $34.0M (Apr 2025).
- It has raised $6.0M across 1 recorded rounds; the latest was Early Stage VC ($6.0M) in Apr 2025.
- Notable investors include Lobe Sciences.
- Cynaptec Pharmaceuticals has filed 1 Form D with the SEC, most recently Apr 2025 ($6.0M sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Cynaptec Pharmaceuticals
Funding rounds
1 roundsAbout Cynaptec Pharmaceuticals
Developer of biopharmaceutical therapies intended to treat neurological and psychiatric disorders. The company's proprietary drug focuses on the treatment of chronic cluster headaches, enabling patients to access novel, targeted treatments through neuroscience-driven innovation aimed at improving mental health outcomes.
- Sector
- Healthcare
- HQ
- Stuart, FL, United States
- Founded
- 2025
- Ownership
- Privately Held (backing)
Cynaptec Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cynaptec Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cynaptec Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.